Growth Hormone Secretagogues Explained: GHRH Analogs, GHRPs, and Ghrelin Mimetics

Growth hormone secretagogues GHRH analogs GHRPs ghrelin mimetics research Durham Peptides Canada

"Growth hormone secretagogue" is an umbrella term, and the confusion in the peptide research space comes from treating it as one category when it's really several. A secretagogue is simply any compound that stimulates the secretion of growth hormone — but the compounds grouped under that label work through fundamentally different mechanisms, target different receptors, and produce different effects on the GH pulse. Understanding the sub-categories is the key to understanding the entire class.

This article maps the growth-hormone secretagogue landscape for Canadian researchers: the major sub-types, how they differ, and where the compounds in the Durham Peptides catalog fit. It's the category-level companion to the compound-specific posts on CJC-1295 + Ipamorelin and CJC-1295 vs Ipamorelin. For the foundational peptide overview, see What Are Peptides?.

First Principles: How Growth Hormone Is Released

Growth hormone is released from somatotroph cells in the anterior pituitary, governed by a balance of signals:

• GHRH (growth-hormone-releasing hormone) — the primary stimulatory signal, acting on the GHRH receptor.

• Ghrelin — a stomach-derived hormone that stimulates GH release through the GHS-R1a receptor.

• Somatostatin — the inhibitory signal that suppresses GH release.

GH is secreted in pulses, not continuously, and that pulsatile pattern is biologically important. Secretagogues are studied precisely because they work with this natural regulatory system rather than replacing it the way exogenous growth hormone does. This is the conceptual divide that defines the category.

Secretagogues vs Exogenous Growth Hormone

The defining distinction of the whole class: secretagogues stimulate the body's own GH release through its existing pathways, whereas exogenous GH is the hormone itself, supplied directly. Researchers study secretagogues for their ability to preserve pulsatility and natural feedback regulation — the GH response remains gated by somatostatin and the body's regulatory loops. This is why short-half-life secretagogues are favored for studying physiological pulsatile dynamics.

The Two Major Secretagogue Sub-Categories

Category 1: GHRH Analogs

These mimic GHRH and act on the GHRH receptor to stimulate GH synthesis and release. They include:

• CJC-1295 (No DAC) — also called Modified GRF (1-29); short half-life, preserves pulsatility.

• Sermorelin — a GHRH(1-29) analog; one of the earliest studied. Durham Peptides does not currently stock sermorelin.

• CJC-1295 with DAC — the long-acting variant; produces sustained rather than pulsatile elevation.

GHRH analogs raise the baseline drive for GH production. Their effect remains subject to somatostatin's inhibitory tone, keeping them within the natural feedback system.

Category 2: Growth Hormone Secretagogue Receptor Agonists (GHRPs and Ghrelin Mimetics)

These act on the GHS-R1a (ghrelin) receptor — a different receptor from GHRH — to amplify GH pulse amplitude and reduce somatostatin tone. They include:

• Ipamorelin — a selective pentapeptide GHS agonist; minimal cortisol/prolactin effect.

• GHRP-6 and GHRP-2 — earlier-generation hexapeptides; effective but less selective, with greater cortisol and prolactin effects. Durham Peptides does not currently stock GHRP-6 or GHRP-2.

• Hexarelin, MK-677 (ibutamoren) — other GHS-pathway compounds with varying half-lives and selectivity.

The defining research advance within this category was selectivity: Ipamorelin was characterized as the first GHS to stimulate GH cleanly, without the off-target cortisol and prolactin elevation seen with earlier GHRPs.

Why GHRH Analogs and GHS Agonists Are Combined

Because the two categories act on different receptors, combining one from each is studied for synergistic GH release. This is the entire rationale behind the CJC-1295 (No DAC) +

Ipamorelin Blend: a GHRH analog (drives synthesis/release) paired with a selective ghrelin mimetic (amplifies the pulse). The combination engages both upstream pathways at once, and published preclinical data suggests this produces greater GH elevation than either category alone. The full mechanism is covered in CJC-1295 + Ipamorelin Blend Explained.

A Map of the Category

Sub-category	Receptor	Examples	Key trait
GHRH analogs	GHRH receptor	CJC-1295 (No DAC), Sermorelin	Drive GH synthesis/release
Selective GHS agonists	GHS-R1a (ghrelin)	Ipamorelin	Amplify GH pulse, selective
Older GHRPs	GHS-R1a (ghrelin)	GHRP-6, GHRP-2	Effective but less selective

What Researchers Examine Across the Category

• Comparative GH-release potency across secretagogue sub-types

• Pulsatile versus sustained GH-secretion patterns

• Selectivity profiles (cortisol/prolactin off-target effects)

• GHRH-analog plus GHS-agonist synergy versus monotherapy

• Downstream IGF-1 responses

Quality Considerations

GH-secretagogue research depends on precise GH and IGF-1 readouts, so material purity and identity directly affect data reliability. Durham Peptides' secretagogue products — CJC-1295 (No DAC), Ipamorelin, and the blend — are Janoshik-verified to ≥99% purity with mass-spec identity confirmation. See How to Read a Janoshik COA and the Lab Resultspage.

Frequently Asked Questions

What is a growth hormone secretagogue? Any compound that stimulates the body's own secretion of growth hormone, working through its existing regulatory pathways rather than supplying GH directly.

What's the difference between a GHRH analog and a GHRP? GHRH analogs (like CJC-1295) act on the GHRH receptor to stimulate GH synthesis/release; GHRPs and ghrelin mimetics (like Ipamorelin) act on the GHS-R1a receptor to amplify GH pulse amplitude. Different receptors.

Is Ipamorelin a GHRP? Ipamorelin acts on the same receptor as GHRPs (GHS-R1a) but is a selective pentapeptide GHS agonist, characterized by minimal cortisol/prolactin effects compared to older GHRPs like GHRP-6.

Why combine a GHRH analog with a ghrelin mimetic? Because they act on different receptors, the combination is studied for synergistic GH release greater than either category alone.

Does Durham Peptides sell sermorelin or GHRP-6? Not currently. The catalog includes CJC-1295 (No DAC), Ipamorelin, and the CJC-1295 + Ipamorelin Blend.

Are secretagogues the same as growth hormone? No. Secretagogues stimulate the body's own GH release; growth hormone is the hormone itself. Secretagogues are studied for preserving the natural pulsatile pattern.

Final Thoughts

The growth-hormone secretagogue class isn't one thing — it's at least two distinct mechanisms (GHRH analogs and GHS/ghrelin agonists) that researchers study both individually and, increasingly, in combination. The CJC-1295 + Ipamorelin Blend is the canonical example of the combination approach: one compound from each category, engaging both pathways for synergistic effect.

For the blend mechanism, see CJC-1295 + Ipamorelin Blend Explained; for the component comparison, see CJC-1295 vs Ipamorelin. Browse the full catalog at durhampeptides.ca/category/all-products.

Selected Research References

1. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the First Selective Growth Hormone Secretagogue. European Journal of Endocrinology. 1998;139(5):552-561. https://pubmed.ncbi.nlm.nih.gov/9849822/

2. Teichman SL, Neale A, Lawrence B, et al. Prolonged Stimulation of Growth Hormone and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GHRH. Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799-805. https://pubmed.ncbi.nlm.nih.gov/16352683/

3. Bowers CY, Momany FA, Reynolds GA, Hong A. On the In Vitro and In Vivo Activity of a New Synthetic Hexapeptide That Acts on the Pituitary to Specifically Release Growth Hormone. Endocrinology. 1984. https://pubmed.ncbi.nlm.nih.gov/1349865/

All products sold by Durham Peptides are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.